IRCT20191005044984N1 IRCT 2019-12-21 Tehran University of Medical Sciences Dolutegravir plus tenofovir alafenamide as a double-drug regimen in HIV positive patients Comparing efficacy of dolutegravir plus tenofovir alafenamide as dual-drug regimen with the standard triple-drug regimen in HIV positive patients 2019-11-22 anticipated 80 Complete https://irct.ir/trial/42809 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible patients will be assigned to the intervention or the control group using simple randomization method. The random numbers will be created by a computer program. The random numbers will be sent to satellite pharmacy of the HIV clinic. Eligible patients will be introduced to this department and treatment regimen will be assigned accordingly. 3 Virologically Undetectable HIV Patients. Intervention 1: Intervention group: The patients' previous standard triple-drug regimen will be changed to the dual-drug regimen including dolutegravir tablet, 50 mg daily plus tenofovir alafenamide tablet, 25 mg daily. This change will be continued for 48 weeks. Patients will be followed during the study period. Intervention 2: Control group: The patients' previous standard triple-drug regimen will be continued. Patients will be followed for 48 weeks. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is After the study, it will be decided upon.